CTOs on the Move

NxStage Medical

www.nxstage.com

 
NxStage System One dialysis machines offer the comfort and flexibility of hemodialysis at home. Discover how our products can improve your quality of life.
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million
  • www.nxstage.com
  • 350, Merrimack Street
    Lawrence, MA USA 01843
  • Phone: 978.687.4700

Executives

Name Title Contact Details

Similar Companies

Argentis Pharmaceuticals

arGentis™ Pharmaceuticals, LLC is a private TN based pharmaceutical company with a mid-stage Orphan Drug treatment (ARG201) for late stage diffuse systemic scleroderma (dcSSc). The company is seeking capital or a partner to complete a Pivotal Clinical Trial which will enable obtaining marketing approval in the EU. The Company has a genotype marker (ROT1) that predicts patient response to treatment by oral tolerance for treatments like ARG201 for dcSSc. Furthermore, arGentis™ has a treatment for Rheumatoid arthritis (ARG301) that is in a Phase I Clinical Trial in the US.

Innocoll

A specialty pharmaceutical company focused on the development and commercialization of pharmaceutical technologies to meet important healthcare challenges

Mighty Oak Medical

Navigate. Dont complicate.™ Personalized patient-specific spine care starts here. Navigate. Dont complicate.™ Personalized patient-specific spine care starts here. Mighty Oak Medical named Solution Provider

Huyabio

HUYABIO is the leader in accelerating the global development of novel biopharmaceutical product opportunities originating in China enabling faster, more cost-effective and lower-risk drug development in the global markets. Through extensive collaboration with biopharmaceutical, academic and commercial organizations, it has built the largest China-sourced compound portfolio covering all therapeutic areas. With offices in the US, Japan, South Korea, Canada, Ireland and eight strategic locations across China, the Company has become a partner of choice to accelerate product development and maximize value globally.

Esperance Pharmaceuticals

Esperance Pharmaceuticals, Inc. is developing a new class of targeted oncology products that selectively kill cancer cells without harming normal cells. Targeting occurs through binding to specific receptors on the cancer cell surface. The novel product candidates destroy dividing and non-dividing cancer cells including those known to be resistant to chemotherapeutics.